Jazz Pharmaceuticals, Inc.

XNASHealth care

Last traded price · USD

$234.66

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:30 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $234.66
Volume: —
Day's high: —
Day's low: —

In brief

Jazz Pharmaceuticals, Inc. is a health care company listed on Nasdaq, valued at about $15.23B.
Its shares closed at $234.66 on 4 Nov 2026, up 70.3% over the past year.
From India you can buy JAZZ in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Jazz Pharmaceuticals, Inc. (JAZZ) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole JAZZ share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade JAZZ options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +1.4% (SPY −1.6%, XLV +13.5%). 3 months: −10.3% (SPY −0.4%, XLV +15.5%). 1 year: +70.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: JAZZ, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $234.66 was 2.0% above its 50-day average ($230.15) and 7.9% above its 200-day average ($217.48). It has closed above the 200-day for 2 sessions, since 3 Nov 2026. The 50-day average crossed above the 200-day on 18 Sep 2025, 284 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
6.9 days to cover short interest
5.9M shares were sold short at the 15 Oct 2026 settlement, 9.0% of the 64.9M shares outstanding; covering them would take 6.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 2.1× its 30-session average on 3 Nov 2026
3 Nov 2026 volume of 1.7M shares was 2.1× the average of the 30 sessions before it (818.5K), as the price rose 7.1%. SPY traded 0.8× its own average that session.
Daily volume against a 30-session baseline · as of 3 Nov 2026
77% of the way up its 52-week range
Closed at $234.66 on 4 Nov 2026: 11.9% below the 52-week high of $266.38 (25 Aug 2026) and 82.2% above the low of $128.80 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+1.4%

6 months+2.7%

1 year+70.3%

5 years+75.7%

Newswire

About

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Website

Notable moves

February 25, 2026
+13.23%
November 17, 2025
+20.57%
March 2, 2022
+12.05%

Jazz Pharmaceuticals, Inc.

XNASHealth care

Last traded price · USD

$234.66

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:30 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $234.66
Volume: —
Day's high: —
Day's low: —

In brief

Jazz Pharmaceuticals, Inc. is a health care company listed on Nasdaq, valued at about $15.23B.
Its shares closed at $234.66 on 4 Nov 2026, up 70.3% over the past year.
From India you can buy JAZZ in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Jazz Pharmaceuticals, Inc. (JAZZ) shares from India?

Do I need the price of a whole JAZZ share to invest?

How much can I invest in US stocks in a year?

Can I trade JAZZ options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +1.4% (SPY −1.6%, XLV +13.5%). 3 months: −10.3% (SPY −0.4%, XLV +15.5%). 1 year: +70.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: JAZZ, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $234.66 was 2.0% above its 50-day average ($230.15) and 7.9% above its 200-day average ($217.48). It has closed above the 200-day for 2 sessions, since 3 Nov 2026. The 50-day average crossed above the 200-day on 18 Sep 2025, 284 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
6.9 days to cover short interest
5.9M shares were sold short at the 15 Oct 2026 settlement, 9.0% of the 64.9M shares outstanding; covering them would take 6.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 2.1× its 30-session average on 3 Nov 2026
3 Nov 2026 volume of 1.7M shares was 2.1× the average of the 30 sessions before it (818.5K), as the price rose 7.1%. SPY traded 0.8× its own average that session.
Daily volume against a 30-session baseline · as of 3 Nov 2026
77% of the way up its 52-week range
Closed at $234.66 on 4 Nov 2026: 11.9% below the 52-week high of $266.38 (25 Aug 2026) and 82.2% above the low of $128.80 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+1.4%

6 months+2.7%

1 year+70.3%

5 years+75.7%

Newswire

About

Website

Notable moves

February 25, 2026
+13.23%
November 17, 2025
+20.57%
March 2, 2022
+12.05%

Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

6.9 days to cover short interest

Volume 2.1× its 30-session average on 3 Nov 2026

77% of the way up its 52-week range

Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

6.9 days to cover short interest

Volume 2.1× its 30-session average on 3 Nov 2026

77% of the way up its 52-week range